Market Intelligence, Clinical Progress, and High-Purity Reagents for Chaperone-Targeted Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HSPA4/HSP70 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HSPA4 Recombinant Protein (WT & ATPase mutants) High purity (>95%), Endotoxin controlled. Sequence Verified. |
View HSPA4 Products |
| Gene Delivery | HSPA4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression. |
View HSPA4 Products |
| Benchmark Ab | Anti-HSPA4 / HSP70 Recombinant Antibody Sequence-verified positive control for IHC/Flow Cytometry. |
View HSPA4 Products |
| Validator | HSPA4 siRNA Set For knockdown verification in target engagement assays. |
View HSPA4 Products |
| Related Target A | HSPA1A (HSP72) Primary HSP70 chaperone; HSPA4 acts as its nucleotide exchange factor. |
View HSPA1A Products |
| Related Target B | BAG3 Co-chaperone regulating HSP70-mediated autophagy and cell survival. |
View BAG3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High homology off-target screening (HSPA4 vs HSPA1A/HSPA8) | Recombinant proteins strictly verified by mass spectrometry and sequence alignment. |
| ATPase activity assay interference | Low endotoxin and ultra-low background free-phosphate formulations. |
| Lack of validated controls | Clinical-grade benchmark antibodies included in the catalog. |
| Off-target siRNA knockdown effects | Sequence-verified pool of 3 siRNA duplexes to ensure specific HSPA4 depletion. |
Live HSPA4/HSP70 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HSPA4/HSP70 therapeutics is intensifying, with major players shifting focus from traditional global heat shock protein inhibition to highly selective, isoform-specific small molecules and membrane-bound HSP70-targeting antibody-drug conjugates (ADCs). As first-generation pan-HSP inhibitors face clinical toxicity limitations, the next wave of R&D is targeting the unique nucleotide exchange factor (NEF) activity of HSPA4 (HSP110 family) to selectively disrupt oncogenic chaperone networks without triggering systemic heat shock responses.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Spin-offs, Biotech | Colorectal Cancer, Leukemia, Glioblastoma | ATPase activity assays & SPR binding kinetics (Need WT and ATP-binding site mutant proteins) |
| Monoclonal Antibodies | Oncoceutics, Multivir | Solid Tumors (Membrane-bound HSP70) | Flow cytometry validation (Need Lentivirus for stable surface expression cell lines) |
| Peptide Vaccines / Immunotherapy | Sela Therapeutics, Cancer Centers | Melanoma, Renal Cell Carcinoma | Peptide-chaperone binding stability (Need highly stable, native-state recombinant antigens) |